ClinicalTrials.Veeva

Menu

Cognitive Effects of Immunomodulatory Drugs in MS

S

Sharon Lynch, MD

Status

Completed

Conditions

Multiple Sclerosis

Study type

Observational

Funder types

Other
Industry

Identifiers

Details and patient eligibility

About

The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).

Full description

In addition this study will compare the patients' personal view of how they are doing, any changes in physical disability, and the frequency and severity of relapses over the three year period.

Enrollment

96 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Diagnosis of RRMS for at least one year,
  • Currently on one of three immunomodulatory drugs (Avonex, Copaxone, or Rebif),
  • Visual Acuity is 20/50 or better,
  • patient has four color vision,
  • Must have at least a high school education

Exclusion criteria

  • History of head injury, drug/alcohol abuse, and/or psychiatric problems, -current diagnosis of a severe or lifethreatening disease other than MS,
  • currently taking immunosuppressant medication,
  • resides greater than 200 miles from the study site

Trial design

96 participants in 4 patient groups

1
Description:
Subjects receiving Avonex
2
Description:
Subjects receiving Rebif
3
Description:
Subjects receiving Copaxone
4
Description:
Healthy controls

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems